Quantitative studies using positron emission tomography for the diagnosis and therapy planning of oncological patients

Hellenic Journal of Nuclear Medicine

Volumn 9, Issue 1, 2006, Pages 10-21

  Dimitrakopoulou Strauss, Antonia ^a   Strauss, Ludwig ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Compartment; Modeling; Non compartment; Oncology; Positron emission tomography; Quantification

Indexed keywords

CARBON 11; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GALLIUM 68; LEVODOPA; WATER O 15;

ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; COMPARTMENT MODEL; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG HALF LIFE; DRUG RETENTION; FOURIER TRANSFORMATION; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LIVER METASTASIS; MAJOR CLINICAL STUDY; PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; PREDICTION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SOFT TISSUE SARCOMA; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT PLANNING; WHOLE BODY RADIATION;

ALGORITHMS; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 33646053156     PISSN: 11081430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Moszynski M, Kapusta M, Wolski D, et al. Energy resolution of scintillation detectors readout with large area avalanche photodiodes and photomulti-pliers. IEEE Trans on Nucl Sci 1998; NS-45: 472-477.
2. Shepp LA, Vardi Y. Maximum likelihood image reconstruction in positron emission tomography. IEEE Trans Med Imag 1982; 1:113-122.
3. Fessler JA, Hero AO. Space alternating generalized expectation maximization algorithm. IEEE Trans Sig Proc 1995; 42: 1223-1227.
4. Daube-Witherspoon ME, Muehlehner G. An iterative image reconstruction algorithm sui-table for volume ECT. IEEE Trans Med Imag 1986; 5: 61-66.
5. Anderson JMM, Mair BA, Rao M, Wu CH. Weighted least-squares reconstruction method for positron emission tomography. IEEE Med Imag 1997;16:159-165.
6. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imag 1994; 13:601-609.
7. Burger C, Buck A. Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med 1997; 38:1818-1823.
8. Ohtake T, Kosaka N, Watanabe T, et al. Noninvasive method to obtain input function for measuring glucose utilization of thoracic and abdominal organs. J Nucl Med 1991; 32: 1432-1438.
9. Keiding S, Munk OL, Schiott KM, Hansen SB. Dynamic 2-(F-18)fluoro-2-deoxy-D-glucose positron emission tomography of liver tumours without blood sampling. Eur J Nucl Med 2000; 27: 407-412.
10. Sokoloff L. Modeling metabolic processes in the brain in vivo. Ann Neur 1984;15:S1-S11.
11. Phelps ME, Huang S-C, Hoffman EJ, et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)-2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979; 6: 371-388.
12. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5: 584-590.
13. Peitgen HO, Juergens H, Saupe D. Length, area and dimension: Measuring complexity and scaling properties. In: Peitgen, Jürgens, Saupe (eds): Chaos and Fractals, New frontiers of science. New York, USA, Springer 1992, 1st ed, pp 192-219.
14. Dimitrakopoulou A, Strauss LG, Clorius JH, et al. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. J Nucl Med 1993; 34: 1075-1081.
15. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, et al. Fluorine-18-F-Fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 1998; 39: 1197-1202.
16. 18F-Labeled Fluorouracil Positron Emission Tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-Fluorouracil. Cancer 1998; 83: 245-253.
17. 18F)Fluordeoxyglucose Positron Emission Tomography imaging in soft tissue sarcomas. Ann Surg 2003; 231: 380-36.
18. Wu H, Dimitrakopoulou-Strauss A, Heichel TO, et al. Quantitative evaluation of skeletal tumors with dynamic Fluorine-18-Fluordeoxyglucose (FDG) PET: SUV in comparison to Patlak analysis. Eur J Nucl Med 2001; 28: 704-710.
19. 18F-FDG Studies in patients with primary and recurrent soft tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med 2001; 42: 713-720.
20. Dimitrakopoulou-Strauss A, Strauss LG, Heichel T, et al. The role of quantitative PET-FDG studies for the differentiation of alignant and benign bone lesions. J Nucl Med 2002; 43: 510-518.
21. Dimitrakopoulou-Strauss A, Strauss LG, Rudi L. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med 2003; 47: 8-13.
22. Dimitrakopoulou-Strauss A, Strauss LG, Rudi J, et al. Dynamic PET-FDG follow-up studies in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy: prediction of therapy outcome and correlation with survival data. J Nucl Med 2004; 45: 1480-1487.
23. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, et al. On the fractal nature of dynamic positron emission tomography (PET) studies. World J Nucl Med 2003; 2: 306-313.
24. Dimitrakopoulou-Strauss A, Strauss LG, Gutzler F, et al. Pharmacokinetic imaging of C-11-Ethanol with PET in eight patients with hepatocellular carcinomas who were scheduled for treatment with percutaneous Ethanol injection. Radiology 1999; 211: 681-686.
25. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989;170: 392-232.
26. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: 1S-93S.
27. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, et al. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995; 22: 434-443.
28. 18F-FDG PET/CT. J Nucl Med 2003; 44:170-176.
29. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18-fluorodeoxyglucose uptake in differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995; 195: 47-52.
30. 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26: 22-30.
31. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the grastroesophageal junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-3065.
32. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake to prognosis. J Nucl Med 1991; 32: 686-691.
33. Chaudhuri NK, Mukherjee KL, Heidelberger C. Studies on fluorinated pyrimidines-VII-the degradative pathway. Biochem Pharmacol 1959; 1: 328-341.
34. Wolf W, Albright MJ, Silver MS, et al. Fluorine-19-NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. Mag Res Imaging 1987; 5: 165-169.
35. Bading JR, Yoo PB, Fissekis JD, et al. Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats. Cancer Res 2003; 63: 3667-3674.
36. Saleem A, Yap J, Osman S, et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in vivo imaging of drug action. Lancet 2000; 355: 2125-2131.
37. 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002; 43: 871-875.
38. 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42:1412-1417.
39. Hubner KF, Buonocore E, Gould HR, et al. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images. Clin Nucl Med 1996; 21: 941-949.
40. Römer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in Non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 4464-4471.
41. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003; 15: 2651-2657.
42. Freedman NMT, Sundaram SK, Kurdziel K, et al. Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans. Eur J Nucl Med 2003; 30: 46-53.
43. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA cytometry and tritated thymidine uptake. J Nucl Med 1993; 34: 419-421.
44. Reisser C, Eichhorn K, Herold-Mende C, et al. Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer 1999; 80: 194-198.
45. Sugawara Y, Zasadny KR, Grossman HB, et al. Germ cell tumor: Differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG and kinetic modeling. Radiology 1999; 211: 249-256.